相关实验视频
Updated: May 16, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.2K
[复发性低血糖症的罕见原因]
Ifigeneia Barmpa1, Apostolos Chatzitomaris1, Eva Maria Lüngen1
1Klinik für Endokrinologie, Diabetologie und Geriatrie, Zentrum für Innere Medizin, Klinikum der Landeshauptstadt Stuttgart gKAöR Katharinenhospital, Stuttgart, Deutschland.
Innere Medizin (Heidelberg, Germany)
|April 1, 2025
概括
非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的疾病,由过多的胰岛素样生长因子2引起. 口服普雷迪尼索隆对患有NICTH进展的患者有效,当手术不是一种选择时.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的内分泌疾病.
- 它是由胰岛素样生长因子2 (IGF-2) 或亲IGF-2的过度分泌引起的.
- 杜吉-波特综合征是一个相关的术语,通常与胸部瘤有关.
研究的目的:
- 描述一个没有瘤进展的NICTH病例.
- 在手术不可行时,评估NICTH的治疗选择.
主要方法:
- 一名患有NICTH和瘤进展的患者接受了口服普雷迪尼索隆治疗.
- 在治疗期间,患者的病情得到了监测.
主要成果:
- 在短时间内观察到瘤进展.
- 开始了口服普雷迪尼索隆治疗,并且似乎是有效的.
- 氧化物和氧化物被认为不推用于这种情况.
结论:
- NICTH需要谨慎管理,特别是当手术解是不可能的.
- 普雷迪尼索隆可能是一个可行的口服治疗选择,用于管理NICTH.
- 对于NICTH,不建议使用特定药物,如二氧化和二氧化.
相关概念视频
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Pathophysiology of Diabetes
822
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
822
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K

